China SXT Pharmaceuticals, Inc.
SXTC · XNASCIK 1723980fmd_0XTW9YKZQX3PKDP19STD3WR18FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2016 to Mar 31, 2026, 18 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 5 | 7 | 7 | 5 | 5 | 3 | 2 | 2 | 2 | 1 |
| Cost of revenue | 3 | 4 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 |
| Gross profit | 2 | 3 | 5 | 3 | 3 | 1 | 0 | 1 | 0 | 0 |
| Research and development | – | – | – | – | – | 0 | 0 | 0 | – | – |
| Selling, general and administrative | – | – | – | – | 5 | 6 | 6 | 3 | 3 | 7 |
| Total operating expenses | 1 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 | 7 |
| Compensation and benefits | – | – | – | – | – | 3 | 1 | 1 | 0 | 0 |
| Impairment of real estate | – | – | – | – | – | – | 0 | 0 | – | – |
| Operating income | 2 | 2 | 2 | (1) | (2) | (5) | (6) | (3) | (3) | (7) |
| Interest expense | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 1 | 1 | 0 |
| Other non-operating income (expense) | (0) | (0) | 0 | (9) | (1) | (0) | (0) | (1) | (1) | 1 |
| Income before taxes | 2 | 2 | 2 | (10) | (3) | (5) | (6) | (3) | (3) | (6) |
| Income tax expense | 0 | 0 | 0 | (0) | (0) | 0 | – | – | – | – |
| Net income from continuing operations | 1 | 1 | 2 | (10) | (3) | (6) | – | – | – | – |
| Net income | 1 | 1 | 2 | (10) | (3) | (6) | (6) | (3) | (3) | (6) |